News

Jagsonpal Pharmaceuticals Limited will hold a board meeting on Wednesday, October 28, 2026, to consider and approve the unaudited financial results (standalone and consolidated) for the quarter ended September 30, 2026, the company said in a filing with the BSE Ltd and National Stock Exchange of India Ltd. The trading window for the company`s securities will remain closed until October 30, 2026, according to a prior communication dated September 25, 2026.

Jagsonpal Pharmaceuticals Limited informed the BSE Ltd and National Stock Exchange of India Ltd that it is enclosing a certificate received from M/s MCS Share Transfer Agent Limited, the Registrar and Share Transfer Agent of the Company, for the quarter ended September 30, 2026, in compliance with Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018.

Jagsonpal Pharmaceuticals Limited has allotted 1,01,825 equity shares of Rs. 2 each to eligible employees under the Jagsonpal Pharmaceuticals Limited Employee Stock Option Plan, 2022, according to a filing with the BSE Ltd and National Stock Exchange of India Ltd. The allotment, which occurred on September 30, 2026, increased the company`s paid-up share capital from Rs. 13,19,14,840 to Rs. 13,21,18,490, comprising 6,60,59,245 equity shares.

Jagsonpal Pharmaceuticals Limited informed the BSE and National Stock Exchange of India that the trading window for its designated persons and their immediate relatives will be closed from Thursday, October 01, 2026, and will reopen 48 hours after the declaration of unaudited financial results for the quarter and six months ended September 30, 2026.

Jagsonpal Pharmaceuticals Ltd. announced a Business Transfer Agreement with Group Pharmaceuticals Limited for the acquisition of its Wellness Portfolio on a going-concern basis by way of slump sale. The initial consideration for the acquisition is Rs 23.7 crores, with an additional consideration potentially reaching up to Rs 23.0 crores linked to FY 2027-28 sales, capped at a total of Rs 46.7 crores. The transaction, expected to close on or before November 1, 2026, will strengthen Jagsonpal’s pharmaceutical portfolio and expand its presence in women’s healthcare, according to a company statement.